BioCentury | Dec 31, 2020
Product Development

Dec. 30 Quick Takes: Approval for Sinopharm vaccine follows report of 79% protection; plus Aprea, Axsome, Serum Institute, Pfizer-BioNTech, Moderna, Inotrem and Actinium

...India Pvt. Ltd. has launched Pneumosil, a pediatric pneumococcal conjugate vaccine it developed with the Program for Appropriate Technology in Health (PATH)...
BioCentury | Mar 19, 2019
Politics & Policy

FDA issues guidances for long-acting PrEP, pediatric HIV drug development

...rilpivirine (TMC278) Long-acting intramuscular cabotegravir Truvada, emtricitabine/tenofovir Bill & Melinda Gates Foundation Gilead Sciences Inc. Johnson & Johnson National Institutes of Health Program for Appropriate Technology in Health (PATH) U.S...
BioCentury | Oct 27, 2017
Clinical News

GSK begins Phase II of malaria vaccine candidate

...of P. falciparum parasitemia, antibody concentration and safety. GSK is developing the vaccine with the Program for Appropriate Technology in Health (PATH)...
BioCentury | May 5, 2017
Company News

WHO to launch GSK's malaria vaccine in Africa

...anywhere. In 2015, EMA’s CHMP recommended its approval. GSK is developing the vaccine with the Program for Appropriate Technology in Health (PATH)...
BioCentury | Sep 1, 2016
Translation in Brief

Malaria's checkpoint sister

...vaccine from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) in July. GSK is developing the vaccine with the Program for Appropriate Technology in Health (PATH)...
BioCentury | Sep 24, 2015
Tools & Techniques

Poppy-free opiates

...artemisinin. That pathway only required expression of up to six plant genes. According to the Program for Appropriate Technology in Health (PATH)...
...and Institutions Mentioned Antheia Inc., Menlo Park, Calif. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Program for Appropriate Technology in Health (PATH)...
BioCentury | Jul 27, 2015
Clinical News

RTS regulatory update

...in national immunization programs once it is approved. GSK is developing the vaccine with the Program for Appropriate Technology in Health (PATH)...
BioCentury | Nov 3, 2014
Clinical News

RSV-F vaccine: Additional Phase II data

...third trimester of pregnancy and in healthy elderly subjects. In 2012, Novavax and the not-for-profit Program for Appropriate Technology in Health (PATH)...
BioCentury | Oct 20, 2014
Company News

Takeda management update

...global vaccine business unit, effective Dec. 1, formerly director of vaccine development global program at Program for Appropriate Technology in Health...
BioCentury | Sep 29, 2014
Clinical News

RSV-F vaccine: Phase II started

...50 healthy women in the third trimester of pregnancy. In 2012, Novavax and the not-for-profit Program for Appropriate Technology in Health (PATH)...
Items per page:
1 - 10 of 69
BioCentury | Dec 31, 2020
Product Development

Dec. 30 Quick Takes: Approval for Sinopharm vaccine follows report of 79% protection; plus Aprea, Axsome, Serum Institute, Pfizer-BioNTech, Moderna, Inotrem and Actinium

...India Pvt. Ltd. has launched Pneumosil, a pediatric pneumococcal conjugate vaccine it developed with the Program for Appropriate Technology in Health (PATH)...
BioCentury | Mar 19, 2019
Politics & Policy

FDA issues guidances for long-acting PrEP, pediatric HIV drug development

...rilpivirine (TMC278) Long-acting intramuscular cabotegravir Truvada, emtricitabine/tenofovir Bill & Melinda Gates Foundation Gilead Sciences Inc. Johnson & Johnson National Institutes of Health Program for Appropriate Technology in Health (PATH) U.S...
BioCentury | Oct 27, 2017
Clinical News

GSK begins Phase II of malaria vaccine candidate

...of P. falciparum parasitemia, antibody concentration and safety. GSK is developing the vaccine with the Program for Appropriate Technology in Health (PATH)...
BioCentury | May 5, 2017
Company News

WHO to launch GSK's malaria vaccine in Africa

...anywhere. In 2015, EMA’s CHMP recommended its approval. GSK is developing the vaccine with the Program for Appropriate Technology in Health (PATH)...
BioCentury | Sep 1, 2016
Translation in Brief

Malaria's checkpoint sister

...vaccine from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) in July. GSK is developing the vaccine with the Program for Appropriate Technology in Health (PATH)...
BioCentury | Sep 24, 2015
Tools & Techniques

Poppy-free opiates

...artemisinin. That pathway only required expression of up to six plant genes. According to the Program for Appropriate Technology in Health (PATH)...
...and Institutions Mentioned Antheia Inc., Menlo Park, Calif. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Program for Appropriate Technology in Health (PATH)...
BioCentury | Jul 27, 2015
Clinical News

RTS regulatory update

...in national immunization programs once it is approved. GSK is developing the vaccine with the Program for Appropriate Technology in Health (PATH)...
BioCentury | Nov 3, 2014
Clinical News

RSV-F vaccine: Additional Phase II data

...third trimester of pregnancy and in healthy elderly subjects. In 2012, Novavax and the not-for-profit Program for Appropriate Technology in Health (PATH)...
BioCentury | Oct 20, 2014
Company News

Takeda management update

...global vaccine business unit, effective Dec. 1, formerly director of vaccine development global program at Program for Appropriate Technology in Health...
BioCentury | Sep 29, 2014
Clinical News

RSV-F vaccine: Phase II started

...50 healthy women in the third trimester of pregnancy. In 2012, Novavax and the not-for-profit Program for Appropriate Technology in Health (PATH)...
Items per page:
1 - 10 of 69